Study guide
9.3 Endocrine, Neurologic & Renal Conditions (Diabetes, Stroke & CKD)
Certified Community Paramedic CP-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Community Paramedicine Foundations
1.1 CP-C Exam Structure, Blueprint & Credentialing 1.2 The Community Paramedic Scope of Practice & Mobile Integrated Healthcare Models
2 Chapter 2: Community Needs & Social Determinants of Health
2.1 Community Health Needs Assessments (CHNA) & Public Health Data 2.2 Social Determinants of Health (SDOH) & Health Disparities 2.3 Community Resource Identification, Referrals & Social Safety Nets
3 Chapter 3: Cultural Humility & Special Vulnerable Populations
3.1 Cultural Competence, Humility & Overcoming Language Barriers 3.2 Special Vulnerable Populations in Community Care (Bariatric, Geriatric & Developmental Needs) 3.3 High-Risk Maternal and Postpartum Care in the Community 3.4 Recognizing and Reporting Abuse, Neglect & Exploitation
4 Chapter 4: Interprofessional Collaboration & Care Planning
4.1 Care Plan Development, Implementation & Patient-Centered Goals 4.2 Interprofessional Communication, SBAR & Case Conferencing 4.3 Chronic Disease Management in Collaborative Care Teams
5 Chapter 5: Healthcare Navigation & Clinical Documentation
5.1 Sub-Acute vs. Acute Condition Triage & Referral Pathways 5.2 Healthcare Systems Coordination, Insurance & ACO Navigation 5.3 Clinical Documentation Standards & Electronic Health Record Exchange 5.4 Patient and Caregiver Advocacy in Complex Systems
6 Chapter 6: Comprehensive Assessment, Screening & Point-of-Care Diagnostics
6.1 Comprehensive Biopsychosocial Health History & Physical Exam 6.2 Point-of-Care Testing (POCT) Modalities & Quality Control 6.3 Diagnostic Laboratory Value Interpretation & Clinical Correlation 6.4 Behavioral Health Screening, Depression & Suicide Risk Assessment 6.5 Toxicology Screening & Substance Use Assessment 6.6 Specimen Collection, Handling, Transportation & Delivery 6.7 Assessing Nutritional, Hydration & Growth Status
7 Chapter 7: Advanced Wound Management & Staging
7.1 Pressure Injury Pathophysiology, Staging & Assessment 7.2 Vascular Ulcers (Venous vs. Arterial) & Diabetic Foot Ulcers 7.3 Advanced Wound Care Therapies, Debridement Boundaries & Dressings
8 Chapter 8: Medication Reconciliation & Pharmacotherapy
8.1 Medication Reconciliation & Identifying Drug-Related Problems 8.2 High-Risk Medications & Safe Deprescribing in Older Adults (Beers Criteria) 8.3 Managing Polypharmacy, Patient Compliance & Storage Safety
9 Chapter 9: Chronic Disease Management & Medical Devices
9.1 Cardiovascular Chronic Disease Management (CHF, Hypertension & CAD) 9.2 Respiratory Chronic Conditions (COPD, Asthma & Oxygen Safety) 9.3 Endocrine, Neurologic & Renal Conditions (Diabetes, Stroke & CKD) 9.4 Home Medical Equipment, Indwelling Lines & Enteral Feeding Tubes 9.5 Post-Surgical Care Procedures & Post-Discharge Sub-Acute Recovery
10 Chapter 10: Infection Prevention & Environmental Safety
10.1 Personal Protective Equipment (PPE) & Residential Infection Control 10.2 Dynamic Situational Awareness, Home Hazards & Personal Safety 10.3 Patient Transfer Biomechanics & Ergonomic Safety in Home Settings
11 Chapter 11: Clinician Resilience & Stress Management
11.1 Compassion Fatigue, Emotional Boundaries & Secondary Trauma 11.2 Occupational Stressors, Burnout Prevention & Peer Support
12 Chapter 12: Health Literacy & Patient Communication Models
12.1 Principles of Adult Learning & Assessing Health Literacy 12.2 Motivational Interviewing Techniques (OARS) & Stages of Change 12.3 The Teach-Back Method & Verifying Patient/Caregiver Comprehension 12.4 Environmental Fall Risk Assessment & Home Injury Prevention
13 Chapter 13: Disease Self-Management, Nutrition & Independence
13.1 Chronic Disease Self-Management & Action Plans 13.2 Medication Adherence Systems & Practical Administration Tools 13.3 Nutritional Guidance, Hydration & Dietary Modifications 13.4 Transition to Independence & Sustainable Community Linkages
14 Chapter 14: Legal Frameworks, Scope & Health Information Privacy
14.1 Community Paramedicine Scope of Practice & Medical Direction 14.2 HIPAA, Protected Health Information (PHI) & Mobile Cybersecurity 14.3 Informed Consent, Refusal of Care & Capacity Assessment
15 Chapter 15: Advance Directives, Palliative Care & Professional Ethics
15.1 Advance Directives, DNR Orders & POLST/MOLST Navigation 15.2 Palliative Care & Hospice Principles in Mobile Integrated Health 15.3 Professional Boundaries, Code of Ethics & Risk Mitigation
9.3 Endocrine, Neurologic & Renal Conditions (Diabetes, Stroke & CKD)
Key Takeaways Explain This Topic AI
American Diabetes Association (ADA) clinical practice standards establish glycemic targets balancing microvascular protection against hypoglycemia risk: fasting capillary glucose 80–130 mg/dL, peak postprandial glucose < 180 mg/dL, and HbA1c < 7.0% for healthy adults, individualized to 7.5–8.5% for frail older adults with high hypoglycemia vulnerability.
Acute conscious hypoglycemia is managed via the 'Rule of 15' (administer 15 grams of fast-acting simple carbohydrates, wait 15 minutes, recheck capillary glucose, and repeat until ≥ 70 mg/dL), whereas severe unconscious hypoglycemia dictates immediate parenteral glucagon (IM/SQ or dry nasal powder) or intravenous dextrose.
Diabetic Ketoacidosis (DKA: absolute insulin deficiency, rapid onset, glucose 250–600 mg/dL, arterial pH < 7.30, serum bicarbonate < 18 mEq/L, positive ketones, anion gap > 12) is clinically distinct from Hyperosmolar Hyperglycemic State (HHS: relative insulin deficiency, insidious onset, glucose > 600–1,000+ mg/dL, serum osmolality > 320 mOsm/kg, profound 8–12 L fluid deficit, minimal/absent ketones).
Secondary prevention following ischemic stroke incorporates antiplatelet therapy, high-intensity statins, tight blood pressure control, and rigorous aspiration pneumonia prevention through formal dysphagia screening and maintaining the patient upright at 90° during meals and for 30 minutes postprandially.
Chronic Kidney Disease staging by GFR (KDIGO 1–5) guides clinical surveillance; hemodialysis vascular access (AV fistula/graft) requires routine assessment for a continuous bruit and palpable thrill with strict prohibition of blood pressures or venipunctures in the access extremity, while cloudy peritoneal dialysis effluent serves as the hallmark indicator of acute bacterial peritonitis.
Last updated: September 2026
9.3 Endocrine, Neurologic & Renal Conditions (Diabetes, Stroke & CKD)
Quick Summary: In Domain 3 (Patient/Client Centric Care), Community Paramedics frequently manage patients burdened by interconnected metabolic, cerebrovascular, and renal pathologies. This section provides the clinical framework required to evaluate diabetes mellitus (individualized HbA₁c targets, the 'Rule of 15' for hypoglycemia, and the critical physiological divergence between DKA and HHS), coordinate post-stroke secondary prevention (antithrombotics, high-intensity statins, and swallowing aspiration precautions), and safeguard patients with Chronic Kidney Disease (KDIGO GFR staging, hemodialysis arteriovenous fistula/graft surveillance, access arm preservation, and peritoneal dialysis peritonitis recognition).
Diabetes mellitus, ischemic cerebrovascular disease, and chronic kidney disease frequently present as a tri-morbid vascular cluster. Pathological macrovascular atherosclerosis and microvascular angiopathy accelerate organ dysfunction, placing these clients at high risk for acute metabolic decompensation, recurrent ischemic stroke, and dialysis access failure.
Diabetes Mellitus: Pathophysiology & Glycemic Goals
Diabetes mellitus comprises metabolic disorders unified by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both:
Type 1 Diabetes (T1D): Organ-specific autoimmune destruction of pancreatic beta cells within the islets of Langerhans, leading to an absolute deficiency of insulin . Patients are dependent on exogenous insulin for survival and are highly susceptible to ketoacidosis.
Type 2 Diabetes (T2D): A progressive disease characterized by peripheral insulin resistance (predominantly in skeletal muscle, adipose tissue, and liver) combined with a progressive secretory defect in beta-cell insulin production. Strongly associated with visceral adiposity, hypertension, dyslipidemia, and metabolic syndrome.
American Diabetes Association (ADA) Glycemic Targets
The Community Paramedic evaluates home capillary blood glucose logs and continuous glucose monitor (CGM) reports against established ADA benchmarks: ADA GLYCEMIC TARGETS FOR COMMUNITY DWELLING ADULTS
- ┌───────────────────────────────────────┬───────────────────────────────┐
- │ Clinical Parameter │ ADA Standard Target │
- ├───────────────────────────────────────┼───────────────────────────────┤
- │ Preprandial / Fasting Glucose │ 80–130 mg/dL (4.4–7.2 mmol/L) │
- │ Peak Postprandial Glucose (1–2h post) │ < 180 mg/dL (10.0 mmol/L) │
- │ Glycated Hemoglobin (HbA1c) │ < 7.0% (53 mmol/mol) │
- └───────────────────────────────────────┴───────────────────────────────┘
- Individualizing Targets: Frail Older Adults
Strict glycemic control (HbA₁c < 7.0%) prevents long-term microvascular complications (retinopathy, nephropathy, neuropathy) over decades. However, in frail older adults with multiple co-morbidities, limited life expectancy, cognitive impairment, or high fall risk, severe hypoglycemia poses an immediate, life-threatening hazard (triggering falls, fractures, myocardial ischemia, stroke, and cardiac arrest).
Frail / High-Risk Older Adult Goal: The ADA recommends relaxing the HbA₁c goal to < 7.5% to 8.0% for older adults with multiple chronic illnesses, and < 8.0% to 8.5% for patients with advanced frailty, dementia, or end-stage chronic conditions, prioritizing the avoidance of hypoglycemia and symptomatic hyperglycemia over tight control.
Hypoglycemia Recognition & The 'Rule of 15'
Hypoglycemia is defined biochemically as a blood glucose concentration < 70 mg/dL (3.9 mmol/L) . In patients treated with sulfonylureas (glipizide, glimepiride, glyburide) or insulin, hypoglycemia can develop rapidly:
Autonomic / Neurogenic Symptoms (Adrenergic Surge): Diaphoresis, tremors, tachycardia, palpitations, hunger, pallor, and intense anxiety (mediated by epinephrine and norepinephrine release).
Neuroglycopenic Symptoms (Brain Glucose Deprivation): Confusion, irritability, slurred speech, visual disturbances, ataxia, paresthesias, focal neurological deficits (which can mimic acute stroke!), seizures, and coma.
Warning
Hypoglycemia Unawareness: Patients with longstanding diabetes or those taking non-selective beta-blockers (such as carvedilol or propranolol) may lose the autonomic warning signs (tremors, tachycardia, diaphoresis) due to blunted sympathoadrenal responses. In these individuals, neuroglycopenia occurs suddenly without preliminary warning symptoms.
The 'Rule of 15' Protocol for Conscious Hypoglycemia
When a conscious patient capable of swallowing displays a capillary glucose < 70 mg/dL, the Community Paramedic executes and reinforces the Rule of 15 : [ BLOOD GLUCOSE < 70 mg/dL ]
- │
- ▼
- 1. ADMINISTER 15g FAST-ACTING CARBOHYDRATE
- 4 oz (1/2 cup) fruit juice or regular soda
- 3 to 4 chewable glucose tablets
- 1 tube of commercial glucose gel
- 5 to 6 hard candies
- (DO NOT use chocolate/milk; fat delays absorption!)
- │
- ▼
- 2. WAIT 15 MINUTES AT COMPLETE REST
- │
- ▼
- 3. RECHECK CAPILLARY BLOOD GLUCOSE
- │
- ┌─────────────────────────┴─────────────────────────┐
- ▼ ▼
- [ Still < 70 mg/dL ] [ ≥ 70 mg/dL ]
Repeat 15g fast-acting carbs; Euglycemia restored!
- Wait another 15 minutes; If next meal is > 1 hour away,
- Recheck capillary glucose. administer a complex carb +
(If 3 cycles fail, escalate!) protein snack (crackers/cheese).
Severe Hypoglycemia Protocol (Unconscious or Aspiration Risk)
If the patient is unconscious, seizing, or unable to swallow safely:
Intravenous Access Present: Administer 10 to 25 grams of Dextrose intravenously (100–250 mL of 10% Dextrose [D10W] is preferred over 50% Dextrose [D50W] to minimize post-resuscitation rebound hyperosmolarity and severe extravasation tissue necrosis).
No Intravenous Access: Administer Glucagon :
Intramuscular (IM) / Subcutaneous (SQ): 1 mg Glucagon reconstitution.
Dry Nasal Powder (Baqsimi): 3 mg single-use nasal spray administered into one nostril (does not require active inhalation; absorbed passively across nasal mucosa).
Exam pearl: Glucagon mobilizes hepatic glycogen stores. In patients with severe starvation, prolonged fasting, or advanced alcoholic liver disease, hepatic glycogen stores are depleted, rendering glucagon ineffective! Immediate IV dextrose or EMS transport is mandatory.
Hyperglycemic Crises: DKA vs. HHS
Community Paramedics must rapidly distinguish between the two life-threatening acute metabolic decompensations of diabetes:
Diagnostic Dimension Diabetic Ketoacidosis (DKA) Hyperosmolar Hyperglycemic State (HHS)
Typical Patient Population Predominantly Type 1 Diabetes (can occur in T2D under extreme stress or with SGLT2i). Exclusively Type 2 Diabetes (typically older, institutionalized, or debility-impaired).
Underlying Pathophysiology Absolute insulin deficiency with unrestrained glucagon, epinephrine, and cortisol excess → massive lipolysis → ketogenesis. Relative insulin deficiency : Sufficient endogenous insulin to suppress lipolysis and ketogenesis, but insufficient to prevent severe hyperglycemia.
Speed of Onset Acute and rapid : Typically evolves over < 24 hours . Insidious and slow : Develops over days to weeks with progressive dehydration.
Serum Glucose Level Typically 250 to 600 mg/dL (13.9–33.3 mmol/L). Note: Euglycemic DKA (< 200 mg/dL) can occur with SGLT2 inhibitors! Markedly elevated: > 600 to 1,200+ mg/dL (33.3–66.6+ mmol/L).
Arterial / Venous pH Acidotic: pH < 7.30 (Severe DKA: pH < 7.00). Normal to near-normal: pH > 7.30 (typically > 7.35).
Serum Bicarbonate (HCO₃⁻) Low: < 18 mEq/L (Severe DKA: < 10 mEq/L). Normal: > 18 mEq/L (typically > 20–24 mEq/L).
Serum & Urine Ketones Strongly positive : Beta-hydroxybutyrate and acetoacetate heavily present in serum and urine. Negative or trace ; minimal hepatic ketogenesis.
Serum Anion Gap Elevated: > 12 mEq/L (Anion Gap = Na + − [ Cl − + HCO 3 − ] \text{Na}^+ - [\text{Cl}^- + \text{HCO}_3^-] Na + − [ Cl − + HCO 3 − ] ). Normal or variable : Typically < 12 mEq/L.
Effective Serum Osmolality Variable: Typically < 320 mOsm/kg. Markedly Hyperosmolar: > 320 mOsm/kg .
Fluid / Hydration Deficit Moderate: 3 to 6 Liters (~100 mL/kg). Profound and lethal: 8 to 12+ Liters (150–200 mL/kg).
Cardinal Clinical Signs Kussmaul respirations (rapid, deep breathing to blow off CO₂), fruity acetone breath odor, abdominal pain, nausea, vomiting. Profound neurological deficits : Stupor, lethargy, focal neurological signs, seizures, coma; absent Kussmaul breathing.
Primary Cause of Mortality Severe metabolic acidosis, hypokalemia-induced dysrhythmias, cerebral edema during rapid therapy. Hypovolemic shock, multiorgan failure, thromboembolism secondary to extreme hyperviscosity.
Stroke: Secondary Prevention & Dysphagia Management
Ischemic stroke accounts for approximately 87% of all cerebrovascular events. Following acute hospitalization and rehabilitation, the Community Paramedic assumes responsibility for monitoring secondary prevention regimens and mitigating the leading preventable cause of post-stroke mortality: aspiration pneumonia .
Secondary Prevention Protocols for Ischemic Stroke
Antithrombotic Therapy:
Non-cardioembolic stroke: Antiplatelet therapy initiated immediately—Aspirin (81–325 mg daily), Clopidogrel (75 mg daily), or combination Aspirin + Extended-Release Dipyridamole. Dual Antiplatelet Therapy (Aspirin + Clopidogrel) is often prescribed for the first 21 to 90 days following high-risk TIA or minor stroke.
Cardioembolic stroke (e.g., Atrial Fibrillation): Direct Oral Anticoagulant (DOAC: Apixaban, Rivaroxaban) or Warfarin (target INR 2.0–3.0).
High-Intensity Lipid-Lowering Therapy: Atorvastatin 80 mg daily or Rosuvastatin 20–40 mg daily, regardless of baseline LDL-C, targeting an LDL reduction ≥ 50% or LDL < 70 mg/dL.
Blood Pressure Optimization: Target blood pressure < 130/80 mmHg using ACE inhibitors, ARBs, or thiazide diuretics once out of the acute window.
Post-Stroke Dysphagia and Aspiration Pneumonia Prevention
Oropharyngeal dysphagia affects over 50% of stroke survivors. Micro-aspiration of colonized oral secretions and ingested food directly causes aspiration pneumonitis and fatal bacterial pneumonia:
Bedside Screening: Before permitting any oral intake (food, pills, or water), verify that the patient has passed a formal speech-language pathologist (SLP) bedside swallow screen.
Dietary Texture Modifications: Strictly verify that the patient's diet adheres to SLP recommendations: mechanically altered foods (pureed or mechanical soft) and thickened liquids (nectar-thick, honey-thick, or spoon-thick / pudding-thick using commercial starch or gum-based thickening agents).
The 90-Degree Mealtime Rule:
The patient must sit fully upright at a 90-degree angle (high Fowler's position) during all meals, snacks, and oral medication administration.
The patient must remain upright at 90 degrees for at least 30 to 45 minutes after eating to prevent postprandial gastroesophageal reflux and aspiration.
Swallowing Compensatory Techniques: Coach the 'chin-tuck' maneuver (flexing the neck so the chin moves toward the chest while swallowing). This biomechanical shift widens the vallecular space, pushes the epiglottis backward, and narrows the airway entrance, significantly reducing the risk of food entering the trachea.
Chronic Kidney Disease & Hemodialysis Access Management
Chronic Kidney Disease (CKD) represents progressive, irreversible loss of renal nephron architecture and excretory function. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines classify CKD into five stages based on the Glomerular Filtration Rate (GFR): KDIGO CKD STAGING BY GFR (mL/min/1.73 m2)
- [Stage 1] ──► [Stage 2] ──► [Stage 3a/3b] ──► [Stage 4] ──► [Stage 5]
- GFR ≥ 90 GFR 60–89 GFR 45–59 (3a) GFR 15–29 GFR < 15
- Normal/High Mild GFR 30–44 (3b) Severe Kidney Failure
- w/ damage Reduction Moderate Reduction (ESRD / Dialysis)
- Hemodialysis Vascular Access Care: AV Fistula vs. AV Graft
When Stage 5 End-Stage Renal Disease (ESRD) is reached, patients require renal replacement therapy. The lifelines for maintenance hemodialysis are surgical vascular accesses constructed in the forearm or upper arm:
Arteriovenous (AV) Fistula (The Gold Standard): A direct, surgically created anastomosis between a native artery and a native vein (e.g., radial artery to cephalic vein). The high arterial pressure causes the vein to dilate and thicken over 2 to 4 months ('maturation'). Carries the lowest rate of infection, lowest thrombosis risk, and longest functional patency.
Arteriovenous (AV) Graft: A synthetic prosthetic conduit (usually polytetrafluoroethylene / PTFE) surgically tunneled under the skin connecting an artery to a vein. Used when native veins are unsuitable. Maturation is faster (2–3 weeks), but carries significantly higher rates of thrombosis, pseudoaneurysm formation, and prosthetic infection.
Physical Assessment: Bruit and Thrill
Every Community Paramedic assessment of an access arm begins with two mandatory physical examination maneuvers:
Palpate for a Thrill: Lightly place the palmar surface of the fingers over the anastomosis and along the length of the access. A patent, healthy fistula produces a continuous, soft, vibratory 'buzzing' sensation called a thrill . A weak, localized thrill or the sudden absence of a thrill indicates acute vascular thrombosis requiring immediate surgical consultation.
Auscultate for a Bruit: Place the diaphragm of the stethoscope lightly over the access. A healthy access produces a continuous, low-pitched, rushing 'whooshing' murmur called a bruit . A high-pitched, harsh, discontinuous, or systolic-only bruit signals intraluminal stenosis!
Caution
Strict Access Arm Protection: Community Paramedics must enforce an absolute, non-negotiable rule: NEVER measure blood pressure, perform venipuncture, insert an intravenous catheter, or allow constrictive clothing/tourniquets on the extremity bearing an AV fistula or graft! External compression or venipuncture induces intraluminal endothelial trauma, microthrombus formation, and permanent access occlusion, destroying the patient's biological lifeline.
Peritoneal Dialysis (PD) & Peritonitis Recognition
Peritoneal dialysis utilizes the patient's semipermeable peritoneal membrane to clear waste and excess fluid. Sterile dialysate fluid is instilled into the peritoneal cavity via a permanently implanted indwelling catheter (Tenckhoff catheter), dwells for several hours, and is then drained into an effluent collection bag.
Cardinal Sign of Acute Bacterial Peritonitis: The appearance of cloudy, turbid peritoneal effluent fluid drained into the bag. Normal effluent is completely clear and pale straw-yellow. Cloudiness is caused by the massive presence of white blood cells (peritoneal fluid leukocyte count > 100/μL with > 50% neutrophils).
Associated Symptoms: Diffuse abdominal pain, rebound tenderness, abdominal wall rigidity, fever, nausea, and vomiting.
Action Plan: If cloudy dialysate is discovered, do not discard the bag! Keep the drained effluent bag intact, contact the patient's nephrologist or peritoneal dialysis center immediately, transport the cloudy fluid to the laboratory for cell count, Gram stain, and culture, and initiate protocolized intraperitoneal antimicrobial therapy.